Virtus Investment Advisers Inc. Has $257,000 Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Virtus Investment Advisers Inc. lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 80.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,980 shares of the biotechnology company’s stock after selling 62,917 shares during the quarter. Virtus Investment Advisers Inc.’s holdings in ADMA Biologics were worth $257,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in ADMA Biologics by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock worth $312,109,000 after purchasing an additional 80,302 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of ADMA Biologics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock valued at $93,187,000 after buying an additional 50,399 shares during the period. Dimensional Fund Advisors LP raised its position in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock worth $80,065,000 after acquiring an additional 643,661 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of ADMA Biologics by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock valued at $64,654,000 after acquiring an additional 102,692 shares during the period. Finally, Perpetual Ltd bought a new position in ADMA Biologics in the fourth quarter valued at about $62,300,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA opened at $19.69 on Monday. The firm’s 50 day simple moving average is $20.49 and its 200 day simple moving average is $18.86. ADMA Biologics, Inc. has a fifty-two week low of $9.22 and a fifty-two week high of $25.67. The company has a market capitalization of $4.70 billion, a price-to-earnings ratio of 70.32 and a beta of 0.57. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same quarter last year, the business posted $0.08 earnings per share. The company’s revenue for the quarter was up 40.2% on a year-over-year basis. As a group, sell-side analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ADMA. StockNews.com cut ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th. Raymond James increased their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a report on Thursday, May 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.